drugset / Trial / NCT06314685

Immunogenicity and Safety of MCV4 in Volunteers Aged 6 Months-5 Years

NCT06314685

Phase 3 Unknown 2450 enrolled Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this study is to evaluate the immunogenicity and safety of Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine in healthy volunteers aged from 3 months to 5 years old.

Timeline

Start
2021-12-10
Primary completion
2024-08-30
Completion
2024-08-30

Indications

No indication recorded.